Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.
Samantha ConroyKarl PangIbrahim JubberSyed A HussainDerek J RosarioMarcus G CumberbatchJames W F CattoAidan P NoonPublished in: BJUI compass (2022)
Our single-institution experience suggests that HIVEC and MMC are tolerable and acceptable. Oncological outcomes in this predominantly elderly, pretreated cohort are promising; however, disease progression was higher in patients pretreated with BCG. Further randomised noninferiority trials comparing HIVEC versus BCG in high-risk NMIBC are required.
Keyphrases
- end stage renal disease
- clinical trial
- chronic kidney disease
- ejection fraction
- newly diagnosed
- skeletal muscle
- muscle invasive bladder cancer
- study protocol
- type diabetes
- peritoneal dialysis
- randomized controlled trial
- adipose tissue
- squamous cell carcinoma
- middle aged
- rectal cancer
- double blind
- radiation therapy
- smoking cessation
- weight loss